ALBT vs SNGX vs MEDP vs CELC

For growth investors, Medpace Holdings, Inc.

(MEDP) is the stronger pick with 20. 0% revenue growth year-over-year, versus 6. 2% for Avalon GloboCare Corp. (ALBT). Medpace Holdings, Inc. (MEDP) offers the better valuation at 28. 1x trailing P/E (25. 2x forward), making it the more compelling value choice. Analysts rate Celcuity Inc. (CELC) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Celcuity Inc.

(CELC) delivered a total return of +381. 6%, compared to -99. 9% for Soligenix, Inc. (SNGX). Over 10 years, the gap is even starker: MEDP returned +1443% versus SNGX's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Avalon GloboCare Corp.

(ALBT) is the lower-risk stock at 1. 11β versus Soligenix, Inc. 's 1. 97β — meaning SNGX is approximately 78% more volatile than ALBT relative to the S&P 500. On balance sheet safety, Soligenix, Inc. (SNGX) carries a lower debt/equity ratio of 36% versus 110% for Avalon GloboCare Corp. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Medpace Holdings, Inc.

(MEDP) is pulling ahead at 20. 0% versus 6. 2% for Avalon GloboCare Corp. (ALBT). On earnings-per-share growth, the picture is similar: Soligenix, Inc. grew EPS 60. 7% year-over-year, compared to -430. 8% for Avalon GloboCare Corp.. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Medpace Holdings, Inc.

(MEDP) is the more profitable company, earning 17. 8% net margin versus -592. 7% for Avalon GloboCare Corp. — meaning it keeps 17. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MEDP leads at 21. 1% versus -369. 6% for ALBT. At the gross margin level — before operating expenses — MEDP leads at 30. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for MEDP: 16.

4% to $498. 86.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Medpace Holdings, Inc.

(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26), +1443% 10Y return). Soligenix, Inc. (SNGX) carries a higher beta of 1. 97 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MEDP: +1443%, SNGX: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ALBT (Real Estate) and SNGX (Healthcare) and MEDP (Healthcare) and CELC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ALBT is a small-cap quality compounder stock; SNGX is a small-cap quality compounder stock; MEDP is a mid-cap high-growth stock; CELC is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.